Phibro Animal Health Corp PAHC
We take great care to ensure that the data presented and summarized in this overview for PHIBRO ANIMAL HEALTH CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PAHC
View all-
Black Rock Inc. New York, NY3.5MShares$158 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.53MShares$68.8 Million0.0% of portfolio
-
State Street Corp Boston, MA894KShares$40.3 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA786KShares$35.4 Million0.06% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL588KShares$26.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny555KShares$25 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA547KShares$24.7 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX486KShares$21.9 Million0.0% of portfolio
-
Nuveen, LLC Charlotte, NC479KShares$21.6 Million0.01% of portfolio
-
Smith, Graham & Co., Investment Advisors, LP448KShares$20.2 Million0.6% of portfolio
Latest Institutional Activity in PAHC
Top Purchases
Top Sells
About PAHC
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for food and companion animals. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for poultry, swine, beef and dairy cattle, aquaculture, and dogs. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. The company also offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. In addition, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Insider Transactions at PAHC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
5,280
-4.81%
|
$232,320
$44.05 P/Share
|
|
Nov 17
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
5,280
-8.76%
|
$232,320
$44.56 P/Share
|
|
Nov 14
2025
|
Jack Bendheim President and CEO |
BUY
Conversion of derivative security
|
Indirect |
55,000
+47.73%
|
-
|
|
Nov 13
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
8,801
-37.45%
|
$387,244
$44.65 P/Share
|
|
Nov 12
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
21,536
-60.53%
|
$969,120
$45.23 P/Share
|
|
Nov 11
2025
|
Jack Bendheim President and CEO |
BUY
Conversion of derivative security
|
Indirect |
15,000
+29.66%
|
-
|
|
Nov 10
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
38,303
-20.72%
|
$1,723,635
$45.27 P/Share
|
|
Nov 07
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
3,520
-5.64%
|
$147,840
$42.86 P/Share
|
|
Nov 05
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
3,520
-2.7%
|
$144,320
$41.41 P/Share
|
|
Nov 04
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
3,520
-2.55%
|
$151,360
$43.31 P/Share
|
|
Nov 04
2025
|
Jack Bendheim President and CEO |
BUY
Conversion of derivative security
|
Indirect |
25,000
+26.47%
|
-
|
|
Oct 30
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
3,520
-7.34%
|
$144,320
$41.07 P/Share
|
|
Oct 29
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
3,520
-6.84%
|
$144,320
$41.66 P/Share
|
|
Oct 28
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
3,520
-6.4%
|
$144,320
$41.56 P/Share
|
|
Oct 24
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
3,520
-6.02%
|
$144,320
$41.75 P/Share
|
|
Oct 23
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
3,520
-5.67%
|
$140,800
$40.18 P/Share
|
|
Oct 22
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
11,859
-16.05%
|
$474,360
$40.27 P/Share
|
|
Oct 21
2025
|
Jack Bendheim President and CEO |
BUY
Conversion of derivative security
|
Indirect |
50,000
+40.36%
|
-
|
|
Oct 20
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
16,075
-40.21%
|
$643,000
$40.38 P/Share
|
|
Oct 17
2025
|
Jack Bendheim President and CEO |
SELL
Open market or private sale
|
Indirect |
700
-1.72%
|
$28,000
$40.03 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 41.5K shares |
|---|---|
| Exercise of conversion of derivative security | 30K shares |
| Open market or private purchase | 5K shares |
| Conversion of derivative security | 175K shares |
| Open market or private sale | 185K shares |
|---|